David A. Siegel Immunic, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q4 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Immunic, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,718 shares of IMUX stock, worth $11,253. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,718

Previous 51,718 79.28%

Holding current value

$11,253

Previous $85,000 88.24%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$1.0 - $1.61 $41,000 - $66,010	-41,000 Reduced 79.28%	10,718 $10,000
Q3 2024 Nov 14, 2024	BUY	$1.08 - $1.95 $4,320 - $7,800	4,000 Added 8.38%	51,718 $85,000
Q2 2024 Aug 14, 2024	SELL	$0.98 - $1.44 $123,088 - $180,864	-125,600 Reduced 72.47%	47,718 $52,000
Q1 2024 May 15, 2024	BUY	$1.14 - $1.53 $29,525 - $39,627	25,900 Added 17.57%	173,318 $228,000
Q4 2023 Feb 14, 2024	SELL	$0.97 - $1.6 $165,191 - $272,480	-170,300 Reduced 53.6%	147,418 $221,000
Q3 2023 Nov 14, 2023	SELL	$1.35 - $2.87 $130,005 - $276,381	-96,300 Reduced 23.26%	317,718 $467,000
Q2 2023 Aug 14, 2023	BUY	$1.33 - $2.51 $18,221 - $34,387	13,700 Added 3.42%	414,018 $1.04 Million
Q1 2023 May 15, 2023	SELL	$1.35 - $2.87 $224,235 - $476,707	-166,100 Reduced 29.32%	400,318 $596,000
Q4 2022 Feb 14, 2023	BUY	$1.13 - $10.8 $473,695 - $4.53 Million	419,200 Added 284.75%	566,418 $792,000
Q3 2022 Nov 14, 2022	BUY	$3.0 - $5.49 $8,100 - $14,823	2,700 Added 1.87%	147,218 $465,000
Q2 2022 Aug 15, 2022	BUY	$3.13 - $12.25 $40,064 - $156,800	12,800 Added 9.72%	144,518 $501,000
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $226,097 - $337,962	-23,700 Reduced 15.25%	131,718 $1.49 Million
Q4 2021 Feb 14, 2022	SELL	$7.34 - $10.25 $71,932 - $100,450	-9,800 Reduced 5.93%	155,418 $1.49 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $23,345 - $38,541	2,900 Added 1.79%	165,218 $1.46 Million
Q2 2021 Aug 16, 2021	SELL	$11.76 - $16.85 $359,856 - $515,610	-30,600 Reduced 15.86%	162,318 $1.99 Million
Q1 2021 May 17, 2021	SELL	$14.21 - $25.3 $120,785 - $215,050	-8,500 Reduced 4.22%	192,918 $3.08 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $1.22 Million - $1.68 Million	82,400 Added 69.23%	201,418 $3.08 Million
Q3 2020 Nov 16, 2020	BUY	$11.74 - $22.0 $1.4 Million - $2.62 Million	119,018 New	119,018 $2.21 Million

Others Institutions Holding IMUX

# of Institutions

Shares Held

51.2M

Call Options Held

824K

Put Options Held

354K

View Full List

About IMMUNIC, INC.

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $32.1M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

More about IMUX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account